CO2020016014A2 - Formulación de proteína de fusión ctla4-ig - Google Patents

Formulación de proteína de fusión ctla4-ig

Info

Publication number
CO2020016014A2
CO2020016014A2 CONC2020/0016014A CO2020016014A CO2020016014A2 CO 2020016014 A2 CO2020016014 A2 CO 2020016014A2 CO 2020016014 A CO2020016014 A CO 2020016014A CO 2020016014 A2 CO2020016014 A2 CO 2020016014A2
Authority
CO
Colombia
Prior art keywords
fusion protein
formulation
ctla4
protein formulation
devoid
Prior art date
Application number
CONC2020/0016014A
Other languages
English (en)
Inventor
M Lakshmi Kanakadurga
Murali Jayaraman
Original Assignee
Dr Reddys Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Reddys Laboratories Ltd filed Critical Dr Reddys Laboratories Ltd
Publication of CO2020016014A2 publication Critical patent/CO2020016014A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención divulga una formulación farmacéutica estable de una proteína de fusión, en donde la formulación contiene regulador, alcohol de azúcar/poliol, aminoácido y tensioactivo, y en donde la formulación está desprovista de sacarosa. Además, la formulación también puede estar desprovista de sal. Las formulaciones de proteína de fusión descritas son formulaciones líquidas que también son adecuadas para liofilización.
CONC2020/0016014A 2018-05-25 2020-12-21 Formulación de proteína de fusión ctla4-ig CO2020016014A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841019606 2018-05-25
PCT/IN2019/050409 WO2019224843A1 (en) 2018-05-25 2019-05-24 Ctla4-ig fusion protein formulation

Publications (1)

Publication Number Publication Date
CO2020016014A2 true CO2020016014A2 (es) 2021-01-29

Family

ID=68616632

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0016014A CO2020016014A2 (es) 2018-05-25 2020-12-21 Formulación de proteína de fusión ctla4-ig

Country Status (10)

Country Link
US (1) US20210179690A1 (es)
EP (1) EP3801606A1 (es)
JP (1) JP2021525255A (es)
CN (1) CN112512562A (es)
AU (1) AU2019274827A1 (es)
BR (1) BR112020023842A2 (es)
CO (1) CO2020016014A2 (es)
SG (1) SG11202011354VA (es)
WO (1) WO2019224843A1 (es)
ZA (1) ZA202007492B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024510480A (ja) * 2021-03-16 2024-03-07 カシーヴ バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー 融合タンパク質の新規製剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI393575B (zh) * 2005-12-20 2013-04-21 必治妥美雅史谷比公司 安定之蛋白質調配物
CN101199484B (zh) * 2006-12-14 2011-08-17 上海抗体药物国家工程研究中心有限公司 一种CTLA4-Ig融合蛋白制剂
WO2011113019A2 (en) * 2010-03-12 2011-09-15 Abbott Biotherapeutics Corp. Ctla4 proteins and their uses

Also Published As

Publication number Publication date
EP3801606A1 (en) 2021-04-14
AU2019274827A1 (en) 2021-01-07
ZA202007492B (en) 2022-09-28
BR112020023842A2 (pt) 2021-04-13
JP2021525255A (ja) 2021-09-24
CN112512562A (zh) 2021-03-16
US20210179690A1 (en) 2021-06-17
SG11202011354VA (en) 2020-12-30
WO2019224843A1 (en) 2019-11-28

Similar Documents

Publication Publication Date Title
CL2019002828A1 (es) Formulación estable de anticuerpos.
CO2019011463A2 (es) Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas
CO2020016008A2 (es) Formulación de proteína de fusión estable
AR097791A1 (es) Formulaciones de anticuerpos anti-pdl1
CL2020001762A1 (es) Formas cristalinas del derivado de 4-pirimidinsulfamida de aprocitentán. (divisional solicitud 201902464)
GT201700184A (es) Nuevas proteínas específicas para pioverdina y pioquelina
BR112017006112A2 (pt) formulação de proteína de fusão recombinante
CO2017007693A2 (es) Formulación acuosa estable de anticuerpo anti-factor de crecimiento celular endotelial vascular (vegf)
BR112018067946A2 (pt) formulações tópicas contendo ciclosporina e usos das mesmas
AR095396A1 (es) Formulaciones de anticuerpo
MX2020005247A (es) Metodos y formulaciones que permiten la modulacion de respuestas inmunitarias relacionadas con la administracion de un farmaco biofarmaceutico.
CO2020013571A2 (es) Formulaciones estables de anticuerpos terapéuticos
EA201892493A1 (ru) Жидкая композиция нейротоксина, стабилизированная триптофаном или тирозином
AR091530A1 (es) Formulacion farmaceutica liquida de un anticuerpo y acetato
DOP2021000170A (es) Formulacion de anticuerpos terapeuticos
CO2020016014A2 (es) Formulación de proteína de fusión ctla4-ig
BR112019008245A2 (pt) composições herbicidas estáveis
BR112018014123A2 (pt) formulação farmacêutica aquosa estável.
MX2020004675A (es) Formulaciones de alcohol de seda.
CL2022001035A1 (es) Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas
CL2020002519A1 (es) Composiciones de erenumab y usos de las mismas
CO2022005737A2 (es) Formulación estable de anticuerpo de integrina
PE20210779A1 (es) NUEVA FORMULACIOìN ESTABLE DE ALTA CONCENTRACIOìN PARA ANTICUERPOS ANTI-FXIa
CO2020013545A2 (es) Formulación estable de anticuerpos
CO2022005207A2 (es) Formulación de anticuerpo que contiene crizanlizumab